Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: This presentation will highlight the importance of risk reduction and emphasizes practical techniques!

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): we give facial ultrasound courses

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: This presentation describes what approaches can be implemented in cases of filler-induced vascular events, aside from hyaluronidase injections. The objective is to give practitioners the tools to deal with such challenging complications.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: How to avoid complications and how to treat them

Introduction: A 62-year-old patient presented ischemia of the right dominant arm and hand after being injected with hyaluronic acid in an upper arm crease. Occlusion of the radial artery, the deep and superficial palmar arch and the common digital arteries, as well as the princeps pollicis artery, was caused by an accidental injection of HA into the brachial artery.

Materials / method: The patient was treated with a catheter-delivered injection of high dose (4.500 units) off- label hyaluronidase into the ulnar and radial artery and additional subcutaneous hyaluronidase application (1500 units) to the forearm and hand. In addition, a plexus catheter was placed 24 hours after initial treatment to achieve sympatholysis and promote vasodilatation. After a second intraarterial hyaluronidase injection (1500 units) combined with lysis therapy via alteplase and adjuvant hyperbaric oxygen therapy.

Results: Full revascularization of the right upper extremity was achieved.

Conclusion: We conclude that off-label treatment with high dose intra-arterial hyaluronidase led to successful restoration of blood circulation after vascular occlusion due to intraarterial HA injection.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: Attendees will be able to understand the vascular mechanisms behind filler-related blindness, identify high-risk injection areas, and implement safe injection and rescue protocols to minimize complications—ensuring better patient outcomes.

Introduction: Filler-induced blindness is a rare but devastating complication in aesthetic medicine. It primarily arises from vascular occlusion in high-risk facial zones. This session explores emerging data, updated protocols, and the supraorbital injection method to reduce the risk of permanent vision loss.

Materials / method: Evidence-based data from peer-reviewed case studies, the Aesthetic Surgery Journal’s 2024 review, and Dr. Treacy’s supraorbital technique form the basis of this analysis. Protocols include hyaluronidase injection strategies, real-time ocular assessment, and emergent management workflows.

Results: Clinicians using supraorbital hyaluronidase injections reported improved vision recovery rates, with some patients regaining near-normal sight. Early recognition and immediate intervention, including ocular assessments and hyaluronidase protocols, significantly reduced permanent blindness risk.

Conclusion: Filler-induced blindness remains a rare but critical emergency. Emphasizing proper anatomy, slow injection techniques, and an immediate rescue plan with supraorbital hyaluronidase is crucial. Advancements in management continue to improve outcomes for at-risk patients.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: One of the most serious complication is ocular complication and will show possible treatment of ocular complication.

Introduction: One of the most serious complication of HA filler injection is ocular complication. Many possible treatments are proposed but non of the treatment has been chosen until now.

Materials / method: We reviewed various treatment of ocular complication treatment induced by HA filler injection and we did experiment of rabbit eye. Retrobulbar HYAL injection and IATT injection.

Results: Retrobulbar HYAL injection and IATT experiment of rabbit showed possible treatment

Conclusion: One of the most important is the time and exact treatment

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability